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While the role of endogenous T cells in antitumor immunity is being debated, little is known about whether
and how T cells promote tumorigenesis. In this issue of Cancer Cell, DeNardo and colleagues demonstrate
that IL-4-producing T cells enhance metastasis by programming macrophages to produce factors that
enhance tumor invasion.For many decades, studies of T cell re-
sponses in cancer focused upon anti-
cancer effects of tumor-specific T cells.
Adoptive transfer studies in mice and hu-
mans certainly validated the capacity of
T cells expanded and activated ex vivo
to kill tumors upon reinfusion. However,
the role of endogenous T cell responses
in tumorigenesis has been less clear and
downright controversial. The original im-
mune surveillance hypothesis suggested
that endogenous immune responses
(likely T cell responses) serve an important
role in inhibiting tumor formation based on
recognition of ‘‘tumor rejection antigens.’’
However, studies demonstrating that T-
cell-deficient mice fail to display higher
rates of chemically induced cancer (Stut-
man, 1974) questioned a role for endoge-
nous T cell responses in tumor inhibition.
More recent findings of increased tumor
incidence in Rag-deficient mice (which
lack T and B cells) or mice deficient in
interferon signaling have resuscitated the
concept of a potential antitumor role for
endogenous T cell and innate immune re-
sponses (Shankaran et. al., 2001). Largely
forgotten in this controversy has been the
potential of T cells to enhance the pro-
cesses of carcinogenesis and tumor dis-
semination.
DeNardo et al. (2009) bring into striking
focus the potential role of T cells in
promotingoneof themost important steps
in cancer progression—metastasis. Using
a transgenic model of Polyoma Middle T
antigen-driven breast cancer tumorigen-
esis (MMTV-PMTmice), they demonstrate
that elimination of endogenous T cells dra-
matically reduces the incidence of lung
metastases while not altering the rate of
developing primary tumors. Further inves-tigations revealed that metastasis rates
dependedspecifically onCD4Tcells since
their elimination reducedmetastasis. How
can these surprising findings be recon-
ciled with earlier findings that tumors arise
more frequently in Rag-deficient mice
(Shankaran et. al., 2001)? One possibility
could be that T cells play different roles
in primary carcinogenesis versus metas-
tasis—possibly even opposite roles. In-
sights into thisparadox requireanappreci-
ation that T cell responses develop along
distinct functional pathways that ulti-
mately can have distinct consequences
for cancer development.
The diversity of programmed T cell acti-
vation pathways is exemplified among
CD4 ‘‘helper T cells.’’ Helper T cells regu-
late immune responses via the production
of specific factors that instruct other cel-
lular elements of the immune system.
There are now three well-defined helper
T cell subsets: Th1, Th2, and Th17 (Zhou
et al., 2009). Th1 effector cells are charac-
terized by production of g-interferon; Th2
cells are defined by production of IL-4 as
well as the related cytokine, IL-13; and the
recently discovered Th17 helper subset is
characterized by production of the cyto-
kine IL-17A. Immune responses induced
by these various helper T cell subsets are
counter-balanced by an inhibitory T cell
subset termed regulatory T cells (Sakagu-
chi et al., 2008). Thegenetic programs that
define each of the different T cell differen-
tiation pathways are regulated by distinct
transcription factors (Zhou et al., 2009).
Beyond infection control, these distinct
helper T cell subsets play varying roles in
immune pathology.
The general consensus among tumor
immunologists is that Th1 cells, basedCancer Ceon their g-interferon production, macro-
phage activation, and enhancement of
killer CD8+ T cells, are critical elements
in antitumor immune responses, but is it
possible that different helper T cell
subsets could promote cancer develop-
ment or metastasis? DeNardo et al.
indeed find this to be the case. They
show that the metastasis-promoting CD4
T cell response in the MMTV-PMT model
is mediated by Th2 responses that
produce IL-4 and IL-13 and that in vivo
blockade with anti-IL-4 antibodies signifi-
cantly inhibited metastasis. This prometa-
static Th2 response appears to be medi-
ated in part by macrophages within the
tumor microenvironment. As with T cells,
there is great plasticity in macrophage
activation programs leading to distinct
effector functions (Mantovani et al.,
2005). In part instructed by helper T cells,
macrophage activation programs have
been divided into M1 type and M2 type.
M1 macrophages, which are induced by
Th1-derived g-interferon, are character-
ized by production of reactive oxygen
species and nitric oxide (NO) and the cyto-
kine IL-12, which further amplifies Th1
responses. Together with CD8 killer cells,
M1 macrophage activation is thought to
be a major mediator of Th1-orchestrated
antitumor responses. DeNardoet al. found
that amajor effector pathway for theprom-
etastatic Th2 responses involves M2
macrophages dependent on IL-4 and IL-
13. M2 macrophages in turn produce
various cytokines such as TGF-b, which
suppresses antitumor immune responses,
and EGFR ligands, which promote tumor
growth and possibly invasiveness. While
previous studies have demonstrated
a role for IL-4 and IL-13 in promotingll 16, August 4, 2009 ª2009 Elsevier Inc. 81
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PreviewsFigure 1. Two Distinct T Cell Differentiation Pathways Lead to Immune Responses that Can
Inhibit or Promote Cancer Progression
The figure demonstrates the concept that the consequences of T cell activation for cancer inhibition
versus promotion depend on the pathway of differentiation. T cells are activated when their T cell receptor
recognizes cognate antigen on an antigen presenting cell (typically a dendritic cell, macrophage or B cell).
Depending on the balance of cytokines present at the time of antigen recognition, T cells can differentiate
along various pathways. Shown in the figure are two pathways of differentiation: the Th1 pathway,
promoted by proinflammatory cytokines such as type 1 interferons (a and b) and IL-12 and the Th2
pathway, promoted by IL-4. Th1 cells, through production of g-interferon, instruct macrophages toward
a tumoricidal M1 program as well as providing signals to activate anti-tumor cytotoxic T cells (CTL).
Thus, a Th1 diffrentiation program inhibits tumor growth and progression. Alternatively, if Th2 responses
develop, macrophages are programmed via IL-4 and/or IL-13 toward a tumor-facilitating M2 differenti-
ating program, characterized by production of growth and pro-angiogenic factors as well as TGF-b, an
inhibitor of antitumor immune responses. Additional T cell differentiation programs, such as Th17 and
regulatory T cells (not shown in figure), likely play distinct roles in the cancer process that is currently under
investigation.cancer growth and metastasis via Stat6
signaling in myeloid cells (Terabe et al.,
2000; Ostrand-Rosenberg et al., 2000),
DeNardo et al. are the first to demonstrate
an example whereby this mechanism is
truly T cell dependent. This work supports
the notion that T cells can impact various
stepsof cancerdevelopmentandprogres-
sion but that their specific role depends on
the type of T cell program initiated, which
in turn determines the nature of down-
stream effector responses (Figure 1).
Beyond Th1 and Th2, the role of Th17-
type immune responses in cancer devel-
opment and progression is likely to be
distinct and is currently being investigated
(Wanget al., 2009).While regulatoryT cells
are well documented to inhibit antitumor
T cell responses (Yamaguchi and Sakagu-
chi, 2006), their role in modulating procar-
cinogenic or prometastatic T cell immunity
remains to be defined.
A major unanswered question in this
study, and all studies implicating endoge-
nous T cell responses in cancer develop-82 Cancer Cell 16, August 4, 2009 ª2009 Elment, is the nature of the antigen(s)
recognized. All T cells require antigen
recognition via their heterodimeric ab
T cell receptor (TCR) in order to become
activated. In the case of infection-induced
carcinogenesis, proteinsexpressedby the
infectious agent represent the likely anti-
gens to engage T cells. However, in the
MMTV-PMT metastasis system, there is
no obvious infectious agent, so the prom-
etastatic Th2 response is likely initiated by
a self-antigen minimally expressed in
normal somatic tissues and upregulated
in the mammary tumors. Clues as to the
identity of the self/tumor antigen(s) may
be drawn from another spontaneous
murine tumor model that has long been
known to depend on CD4 T cells—the B
cell lymphomas that arise frequently in
SJL-strain mice. These lymphomas in-
volve the activation of an endogenous
mammary tumor virus encoding a super-
antigen that stimulates CD4 T cells to
produce Th2 cytokines just as in the
MMTV-PMT model (Tsiagbe et al., 1993).sevier Inc.Each different superantigen selectively
activates T cells whose TCR utilizes dis-
tinct Vb segment. If an endogenous retro-
viral encoded superantigen is indeed the
instigator in the MMTV-PMT system as
with the SJL lymphomas, metastases
would be dependent on CD4 T cells pre-
dominantly expressing a single Vb seg-
ment.
Finally, the therapeutic relevance of
these findings should not be overlooked.
If distinct T cell programs selectively
enhance or inhibit cancer progression, it
should be possible to ‘‘redirect’’ tumor-
specific T cell programs from procancer
to anticancer. Since the cytokines, recep-
tors, and signaling pathways responsible
for initiating and maintaining each of
the helper T cell programs are becoming
well defined, it should indeed be possible
to block certain procarcinogenic differen-
tiation programs while promoting anti-
tumor programs. If we look carefully, we
may find that there are already antibodies
and drugs on shelves able to accomplish
just that.
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